Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- MHLW Panel OKs Onoact for Pediatric Tachyarrhythmia and More Drugs
August 5, 2022
- Evaluate Shionogi COVID Pill Based on Omicron Symptoms: Komeito Lawmakers
August 5, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Now in Line for Approval
August 4, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- Japan OKs FY2023 Budget Guidelines, 560 Billion Yen Cap for Social Security Cost Rise
August 1, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Clear MHLW Panel, September Approval Likely
August 1, 2022
- MHLW Flags Hoarding of Acetaminophen, Ayumi Stops Supply of 2 Dosage Forms
August 1, 2022
- PMDA Reviewing Safety Risks for Plaquenil, Cyramza
August 1, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
- Online Submissions for Partial Changes of Generics to Start from October
July 29, 2022
- MHLW Panel OKs 60 More Health Damage Claims for COVID-19 Vaccines
July 29, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…